EIZO (6737) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
18 Mar, 2026Executive summary
Net sales for the first half of FY2024 were JPY36.8B, down 1% year-over-year, with operating income at JPY0.8B, a 49.3% decrease, and net income at JPY0.7B, down 67.1% compared to the same period last year.
Comprehensive income turned negative at JPY(0.28)B, compared to JPY6.57B in the prior year.
Sales and profit declined due to weak demand in Business & Plus (B&P) and Healthcare (HC) segments, impacted by economic slowdown, stock adjustments, and postponed projects.
Vertical & Specific (V&S) segment saw increased sales, especially in Air Traffic Control, while Amusement (AMU) sales dropped after a strong prior year.
Financial highlights
Gross profit margin decreased to 32.5% from 33.1% year-over-year, with gross profit at JPY11.97B, down from JPY12.29B.
Ordinary profit fell 66.6% year-over-year to JPY1.07B.
Selling, general, and administrative expenses rose 4.6% year-over-year, driven by higher wages and R&D investment.
Foreign exchange loss of JPY0.39B realized, compared to a gain in the previous year.
Cash and equivalents increased to JPY18.8B, while inventories and accounts receivable declined.
Outlook and guidance
FY2024 full-year net sales projected at JPY81.0B, up 0.7% year-over-year, with operating income expected to reach JPY4.0B.
Net income forecasted to decrease to JPY3.4B, reflecting a 37.7% drop year-over-year.
Earnings per share forecast for FY2025 is JPY82.61, reflecting the share split.
B&P and HC segments expected to remain weak due to delayed demand recovery in Europe and China, while V&S sales are projected to increase.
SG&A expenses to be controlled below original plan.
Latest events from EIZO
- Profits fell on weak demand, but full-year growth and a share split are forecast.6737
Q1 202518 Mar 2026 - Profits dropped despite stable sales, with unchanged guidance and a recent share split.6737
Q3 202518 Mar 2026 - Flat sales and lower profit, but FY2026 outlook targets growth and higher dividends.6737
Q4 202518 Mar 2026 - Sales and profits fell on European weakness, but margin and new products support future outlook.6737
Q1 202618 Mar 2026 - Healthcare and Amusement drove 2.9% sales growth, but profits were pressured by higher SG&A.6737
Q2 202618 Mar 2026 - Net sales rose, but profit outlook was cut due to higher costs and weak European demand.6737
Q3 202618 Mar 2026